U.K. fusion firm Astral Systems has signed a memorandum of understanding with Brazil’s Institute for Energy and Nuclear Research (IPEN/CNEN) to explore a range of technological pathways for producing medical isotopes.
IPEN/CNEN is one of Brazil's leading radiopharmaceutical producers. The partnership will initially focus on using Astral’s multistate fusion neutron generation technology to establish a new supply stream for actinium-225, a rare radioisotope used in cancer treatment, according to an announcement. The companies also plan to deploy a next-generation neutron technology device as part of the collaboration.
